Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100PGWR
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥241m2021-04-01 → 2021-09-30Cons.Net sales
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Operating income−¥949m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥952m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥1.2bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥1.2bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.7bnat 2022-09-30Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥3.7bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥340mat 2022-09-30Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥3.1bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥468m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-6.742021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.722021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥195m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥243m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥234m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥8m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥63m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-09-30−¥691m
—segment totalrevenue2021-04-01 → 2021-09-30¥249m
—segment totalrevenue external2021-04-01 → 2021-09-30¥241m
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥8m
—segment totalsegment profit2021-04-01 → 2021-09-30−¥754m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 443
ItemContextValueUnit
Gain on reversal of subscription rights to shares eiPrior1YTDDuration47853000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration37755000JPY
Extraordinary incomePrior1YTDDuration47902000JPY
Extraordinary incomeCurrentYTDDuration37755000JPY
Impairment loss elPrior1YTDDuration324781000JPY
Impairment loss elCurrentYTDDuration6941000JPY
Extraordinary lossPrior1YTDDuration324781000JPY
Extraordinary lossCurrentYTDDuration6941000JPY
Income before income taxesPrior1YTDDuration-1228924000JPY
Income before income taxesCurrentYTDDuration-612760000JPY
Income taxes currentPrior1YTDDuration1448000JPY
Income taxes currentCurrentYTDDuration1373000JPY
Income taxes deferredPrior1YTDDuration-645000JPY
Income taxes deferredCurrentYTDDuration-338000JPY
Income taxesPrior1YTDDuration803000JPY
Income taxesCurrentYTDDuration1035000JPY
Profit lossPrior1YTDDuration-1229728000JPY
Profit lossCurrentYTDDuration-613796000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-1229728000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-613796000JPY
Profit lossPrior1YTDDuration-1229728000JPY
Profit lossCurrentYTDDuration-613796000JPY
Comprehensive incomePrior1YTDDuration-1229728000JPY
Comprehensive incomeCurrentYTDDuration-613796000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-1229728000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-613796000JPY
Income before income taxesPrior1YTDDuration-1228924000JPY
Income before income taxesCurrentYTDDuration-612760000JPY
Depreciation and amortization ope cfPrior1YTDDuration11047000JPY
Depreciation and amortization ope cfCurrentYTDDuration－JPY
Impairment loss ope cfPrior1YTDDuration324781000JPY
Impairment loss ope cfCurrentYTDDuration6941000JPY
Share based compensation expenses ope cfPrior1YTDDuration15317000JPY
Share based compensation expenses ope cfCurrentYTDDuration13642000JPY
Gain on sales of non current assets ope cfPrior1YTDDuration-49000JPY
Gain on sales of non current assets ope cfCurrentYTDDuration－JPY
Gain on reversal of subscription rights to shares ope cfPrior1YTDDuration-47853000JPY
Gain on reversal of subscription rights to shares ope cfCurrentYTDDuration-37755000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration123862000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration350496000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-24826000JPY
Decrease increase in inventories ope cfCurrentYTDDuration102862000JPY
Decrease increase in advance payments ope cfPrior1YTDDuration-163072000JPY
Decrease increase in advance payments ope cfCurrentYTDDuration5582000JPY
Decrease increase in consumption taxes refund receivable ope cfPrior1YTDDuration-57711000JPY
Decrease increase in consumption taxes refund receivable ope cfCurrentYTDDuration28085000JPY
Increase decrease in accounts payable other ope cfPrior1YTDDuration-22959000JPY
Increase decrease in accounts payable other ope cfCurrentYTDDuration-290616000JPY
Increase decrease in contract liabilities ope cfPrior1YTDDuration－JPY
Increase decrease in contract liabilities ope cfCurrentYTDDuration-22268000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass